LianBio up as cancer drug succeeds in mid-stage trial

LianBio

06/06/2023 21:33

** Shares of biotech co LianBio  LIAN.O  rise 8.2% to $2.77
in extended trade    
    ** Says its experimental drug infigratinib in a mid-stage
trial showed partial response or complete response in Chinese
patients with a type of gastric cancer 
    ** Co also adds that based on the study data, China National
Medical Products Administration (NMPA) granted "breakthrough
therapy" tag to infigratinib for treating gastric cancer
    ** As of last close, LIAN shares up ~56% this year 

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))